Printer Friendly

BIO-TECHNOLOGY GENERAL AND MEMORIAL SLOAN-KETTERING INITIATE A PHASE II STUDY OF RECOMBINANT HUMAN GROWTH HORMONE IN CANCER PATIENTS

BIO-TECHNOLOGY GENERAL AND MEMORIAL SLOAN-KETTERING INITIATE A PHASE II
 STUDY OF RECOMBINANT HUMAN GROWTH HORMONE IN CANCER PATIENTS
 NEW YORK, Oct. 1 /PRNewswire/ -- Bio-Technology General Corp. (NASDAQ: BTGC) today announced the initiation of a Phase II efficacy study of its recombinant human growth hormone (r-hGH, BioTropin(TM)) in pancreatic cancer patients. The study is being conducted at Memorial Sloan-Kettering Cancer Center in New York, where a Phase I hGH safety study in cancer patients and normal volunteers was recently completed.
 Many advanced pancreatic cancer patients suffer from a wasting syndrome known as cachexia. To-date, efforts at preventing or attenuating cachexia in these patients have largely failed. Recent short-term studies have shown that cancer patients treated with BTG's hGH were responsive to the anabolic effect of the hormone.
 "We believe that this study is the first to investigate the efficacy of hGH in treating or preventing cachexia in cancer patients," stated Sim Fass, president and chief executive officer of Bio-Technology General Corp. "We are hopeful the hGH could provide a breakthrough in the treatment of this devastating disease."
 The company is currently conducting additional clinical studies aimed at assessing the utility of hGH in the treatment of HIV-infected patients, and in the prevention of muscle atrophy in elderly patients hospitalized with hip fracture.
 Bio-Technology General Corp. is a leading biotechnology company principally engaged in the research, development and manufacture of genetically engineered products for human and animal health care.
 -0- 10/01/92
 CONTACT: Leah Berkovits of Bio-Technology General, 212-239-0450; Don Weinberger of Strategic Growth International, 212-826-9622 (investors); or Anthony Russo of Noonan/Russo Communications, 212-979-9180, both for Bio-Technology General
 (BTGC) CO: BIO-TECHNOLOGY GENERAL CORP. IN: MTC ST: NY -- NY019 -- X970 10/01/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1992
Words:283
Previous Article:DU PONT MERCK'S 'CARDIOLITE' INDICATED FOR USE IN EVALUATING ISCHEMIA
Next Article:NEW JERSEY BANKERS PLEASED WITH SECOND QUARTER RESULTS
Topics:


Related Articles
PDL HUMANIZED ANTIBODY FOR MYELOID LEUKEMIA IS SAFE AND CAUSES NO IMMUNE RESPONSE IN PHASE I TRIAL
CYTOGEN Announces Issuance of PSMA Patent
Investigators Report Activity in Clinical Studies of Genta's Antisense Product In Drug-Resistant Cancers.
Results of Phase I/II Trial of MDX-447 Cancer Product Reported at ASCO Meeting.
Viragen Announces $30 Million Financing By Ladenburg Thalmann.
Viragen Appoints New Directors To European Subsidiary.
Viragen to Present at 'BIO-Europe 2004'.
Viragen to Present at 'BIO-Europe 2004'.
Viragen Reports Williams de Broe Increases Sales Forecasts for Multiferon(R) Based on Cancer Study.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters